The next focusIR Investor Webinar takes places on Weds 10th July at 6 PM with guest speakers from Pyx Resources (PYX), Helium One (HE1), Fulcrum Metals (FMET) and Metals One (MET1). Please register here.

Less Ads, More Data, More Tools Register for FREE
Bradda Head  Lithium exceeds targets, secures US$3 million royalty and moves closer to production
Bradda Head Lithium exceeds targets, secures US$3 million royalty and moves closer to productionView Video
IntelliAM aiming for significant growth with £5 million Aquis IPO
IntelliAM aiming for significant growth with £5 million Aquis IPOView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 90.94
Bid: 93.35
Ask: 93.36
Change: -0.13 (-0.143%)
Spread: 0.01 (0.011%)
Open: 91.24
High: 91.56
Low: 90.53
Prev. Close: 90.23
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Europe's STOXX 600 slips, but marks seventh week of gains

Fri, 02nd Dec 2022 17:15

Sanofi slips amid Horizon deal talks

*

STOXX 600 gains 0.6% this week

Dec 2 (Reuters) - European shares fell back on Friday after two days of strong gains that helped the STOXX 600 index notch up its seventh straight week of rises amid signs of China re-opening its economy and easing worries about interest-rate hikes.

The pan-European index closed 0.2% lower after rallying 1.5% in the last two sessions. The index gained 0.6% over the week, and registered its longest weekly winning streak since April 2021.

Energy and technology stocks were among the biggest drags on the broader index, offsetting gains in real estate and retailers.

"There appears to be some profit-taking after sessions characterised mostly by risk-on appetite. Optimism towards the economic reopening in China has helped drive gains," Victoria Scholar, head of investment at Interactive Investor, said.

Chinese officials this week softened their stance on strict COVID curbs that have hit global growth amid protests in the country.

Rate-sensitive technology stocks also took a hit as euro zone government bond yields rose in line with a move in U.S. Treasury yields after data showed U.S. employers hired more workers than expected in November and increased wages despite mounting worries of a recession.

"Strong job creation and a big increase in wages underscore the Federal Reserve's argument that a lot more work needs to be done to get inflation under control," James Knightley, chief international economist at ING, said in a note.

"It has certainly jolted the market. But with recessionary fears lingering, market participants will remain sceptical over how long the strong performance can last."

Data this week from Europe showing cooling inflation and falling German retail sales and exports have also made the case for the European Central Bank to opt for a smaller hike.

However, ECB Vice-President Luis de Guindos said on Friday the central bank needs to focus on bringing inflation down to its 2% mid-term goal and therefore keep raising interest rates despite a recent deceleration in the pace of price rises.

Among individual stocks, French drugmaker Sanofi fell 1.9% after saying that if it bid for biotech company Horizon Therapeutics Plc, it would do so in cash.

Horizon, with a market capitalization of about $18 billion, is also in talks with Amgen Inc and Johnson & Johnson unit Janssen Global Services over potential takeover offers.

Credit Suisse jumped 9.3% after 12 straight days of losses that sent the stock to a record low. The Swiss lender is looking to speed up cost cutting as the revenue outlook worsens. (Reporting by Susan Mathew in Bengaluru; Editing by Saumyadeb Chakrabarty, Savio D'Souza and Andrew Heavens)

More News
1 Jul 2024 23:37

Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge

July 1 (Reuters) - A Delaware judge rebuffed a request by GSK and other drugmakers to appeal a ruling allowing more than 70,000 lawsuits claiming that the heartburn drug Zantac caused cancer to go forward.

Read more
27 Jun 2024 13:00

German vaccine panel endorses Astra-Sanofi's RSV shot for infants

FRANKFURT, June 27 (Reuters) - Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infection RSV.

Read more
20 Jun 2024 16:01

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.

Read more
11 Jun 2024 00:32

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

June 10 (Reuters) -

Read more
10 Jun 2024 22:49

Latest trial over Zantac cancer claims called off as plaintiff drops case

June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced.

Read more
7 Jun 2024 19:34

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total number of affected states, which have been encouraged to ramp up testing efforts at the request of government officials.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more
27 May 2024 06:00

US, European nations consider vaccinating workers exposed to bird flu

CHICAGO/LONDON, May 27 (Reuters) - The United States and Europe are taking steps to acquire or manufacture H5N1 bird flu vaccines that could be used to protect at-risk poultry and dairy workers, veterinarians and lab technicians, government officials said, moves influenza experts say could curb the threat of a pandemic.

Read more
23 May 2024 19:21

Zantac not a cause of woman’s cancer, jury says in first trial over drug

CHICAGO, May 23 (Reuters) - A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making similar allegations.

Read more
22 May 2024 22:59

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 22 (Reuters) -

Read more
10 May 2024 17:21

STOXX 600 closes at record high on earnings, rate cut optimism

Rio Tinto considered bid for BHP-target Anglo American -report

*

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.